<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">37443561</PMID><DateRevised><Year>2023</Year><Month>07</Month><Day>18</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2075-4418</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><Issue>13</Issue><PubDate><Year>2023</Year><Month>Jun</Month><Day>26</Day></PubDate></JournalIssue><Title>Diagnostics (Basel, Switzerland)</Title><ISOAbbreviation>Diagnostics (Basel)</ISOAbbreviation></Journal><ArticleTitle>Concentrations of Serum Brain Injury Biomarkers Following SARS-CoV-2 Infection in Individuals with and without Long-COVID-Results from the Prospective Population-Based COVI-GAPP Study.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">2167</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/diagnostics13132167</ELocationID><Abstract><AbstractText>It is unknown whether neurological symptoms are associated with brain injury after SARS-CoV-2 infections and whether brain injury and related symptoms also emerge in Long-COVID patients. Biomarkers such as serum neurofilament light chain (sNfL) and glial fibrillary acidic protein (sGFAP) can be used to elucidate neuro-axonal and astroglial injuries. We investigated whether these biomarkers are associated with COVID-19 infection status, associated symptoms and Long-COVID. From 146 individuals of the general population with a post-acute, mild-to-moderate SARS-CoV-2 infection, sNfL and sGFAP were measured before, during and after (five and ten months) the infection. Individual symptoms and Long-COVID status were assessed using questionnaires. Neurological associated symptoms were described for individuals after a mild and moderate COVID-19 infection; however, sNfL (<i>p</i> = 0.74) and sGFAP (<i>p</i> = 0.24) did not change and were not associated with headache (<i>p</i> = 0.51), fatigue (<i>p</i> = 0.93), anosmia (<i>p</i> = 0.77) or ageusia (<i>p</i> = 0.47). In Long-COVID patients, sGFAP (<i>p</i> = 0.038), but not sNfL (<i>p</i> = 0.58), significantly increased but was not associated with neurological associated symptoms. Long-COVID status, but not post-acute SARS-CoV-2 infections, may be associated with astroglial injury/activation, even if neurological associated symptoms were not correlated.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Telser</LastName><ForeName>Julia</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Dr. Risch Medical Laboratory, 9490 Vaduz, Liechtenstein.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Dr. Risch Medical Laboratory, 9470 Buchs, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medical Sciences, Private University in the Principality of Liechtenstein (UFL), 9495 Triesen, Liechtenstein.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grossmann</LastName><ForeName>Kirsten</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-0460-3736</Identifier><AffiliationInfo><Affiliation>Dr. Risch Medical Laboratory, 9490 Vaduz, Liechtenstein.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medical Sciences, Private University in the Principality of Liechtenstein (UFL), 9495 Triesen, Liechtenstein.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weideli</LastName><ForeName>Ornella C</ForeName><Initials>OC</Initials><Identifier Source="ORCID">0000-0003-2339-9440</Identifier><AffiliationInfo><Affiliation>Dr. Risch Medical Laboratory, 9490 Vaduz, Liechtenstein.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Soneva Fushi, Boduthakurufaanu Magu, Male 20077, Maldives.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hillmann</LastName><ForeName>Dorothea</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Dr. Risch Medical Laboratory, 9470 Buchs, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aeschbacher</LastName><ForeName>Stefanie</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-8134-2421</Identifier><AffiliationInfo><Affiliation>Dr. Risch Medical Laboratory, 9490 Vaduz, Liechtenstein.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardiology, University Hospital of Basel, 4031 Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wohlwend</LastName><ForeName>Niklas</ForeName><Initials>N</Initials><Identifier Source="ORCID">0009-0008-3752-7910</Identifier><AffiliationInfo><Affiliation>Dr. Risch Medical Laboratory, 9490 Vaduz, Liechtenstein.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine, University of Bern, 3012 Bern, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Velez</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Dr. Risch Medical Laboratory, 9490 Vaduz, Liechtenstein.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of St. Gallen, 9000 St. Gallen, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kuhle</LastName><ForeName>Jens</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Neurologic Clinic and Policlinic, MS Center and Research Center of Clinical Neuroimmunology and Neuroscience Basel (RC2NB), University Hospital Basel, University of Basel, 4031 Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maleska</LastName><ForeName>Aleksandra</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Neurologic Clinic and Policlinic, MS Center and Research Center of Clinical Neuroimmunology and Neuroscience Basel (RC2NB), University Hospital Basel, University of Basel, 4031 Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benkert</LastName><ForeName>Pascal</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Neurologic Clinic and Policlinic, MS Center and Research Center of Clinical Neuroimmunology and Neuroscience Basel (RC2NB), University Hospital Basel, University of Basel, 4031 Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Risch</LastName><ForeName>Corina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Dr. Risch Medical Laboratory, 9490 Vaduz, Liechtenstein.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Dr. Risch Medical Laboratory, 9470 Buchs, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Conen</LastName><ForeName>David</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-2459-5251</Identifier><AffiliationInfo><Affiliation>Population Health Research Institute, McMaster University, Hamilton, ON L8L 2X2, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Risch</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Dr. Risch Medical Laboratory, 9490 Vaduz, Liechtenstein.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Dr. Risch Medical Laboratory, 9470 Buchs, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Laboratory Medicine, Kantonsspital Graub&#xfc;nden, 7000 Chur, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Risch</LastName><ForeName>Lorenz</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Dr. Risch Medical Laboratory, 9490 Vaduz, Liechtenstein.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Dr. Risch Medical Laboratory, 9470 Buchs, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medical Sciences, Private University in the Principality of Liechtenstein (UFL), 9495 Triesen, Liechtenstein.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>101005177</GrantID><Agency>Innovative Medicines Initiative</Agency><Country/></Grant><Grant><GrantID>na</GrantID><Agency>The Government of the Principality of Liechtenstein</Agency><Country/></Grant><Grant><GrantID>na</GrantID><Agency>The Princely House of the Principality of Liechtenstein</Agency><Country/></Grant><Grant><GrantID>na</GrantID><Agency>The Hanela Foundation in Switzerland</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>06</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Diagnostics (Basel)</MedlineTA><NlmUniqueID>101658402</NlmUniqueID><ISSNLinking>2075-4418</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">GFAP</Keyword><Keyword MajorTopicYN="N">NfL</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">glial fibrillary acidic protein</Keyword><Keyword MajorTopicYN="N">neurofilament light chain</Keyword><Keyword MajorTopicYN="N">serum biomarker</Keyword></KeywordList><CoiStatement>Lorenz Risch and Martin Risch are key shareholders of the Dr Risch Medical Laboratory. David Conen has received speaker fees from DMS/Pfizer and Servier, as well as consulting fees from Roche Diagnostics and Trimedics, all outside of the current work. The other authors have no financial or personal conflict of interest to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>5</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>6</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>6</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>7</Month><Day>14</Day><Hour>13</Hour><Minute>9</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>7</Month><Day>14</Day><Hour>13</Hour><Minute>8</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>7</Month><Day>14</Day><Hour>1</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>6</Month><Day>26</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37443561</ArticleId><ArticleId IdType="pmc">PMC10340196</ArticleId><ArticleId IdType="doi">10.3390/diagnostics13132167</ArticleId><ArticleId IdType="pii">diagnostics13132167</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Whittaker A., Anson M., Harky A. Neurological Manifestations of COVID-19: A systematic review and current update. Acta Neurol. Scand. 2020;142:14&#x2013;22. doi: 10.1111/ane.13266.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ane.13266</ArticleId><ArticleId IdType="pmc">PMC7273036</ArticleId><ArticleId IdType="pubmed">32412088</ArticleId></ArticleIdList></Reference><Reference><Citation>Chou S.H.-Y., Beghi E., Helbok R., Moro E., Sampson J., Altamirano V., Mainali S., Bassetti C., Suarez J.I., McNett M., et al. Global Incidence of Neurological Manifestations Among Patients Hospitalized With COVID-19&#x2014;A Report for the GCS-NeuroCOVID Consortium and the ENERGY Consortium. JAMA Netw. Open. 2021;4:e2112131. doi: 10.1001/jamanetworkopen.2021.12131.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.12131</ArticleId><ArticleId IdType="pmc">PMC8114143</ArticleId><ArticleId IdType="pubmed">33974053</ArticleId></ArticleIdList></Reference><Reference><Citation>Helms J., Kremer S., Merdji H., Clere-Jehl R., Schenck M., Kummerlen C., Collange O., Boulay C., Fafi-Kremer S., Ohana M., et al. Neurologic Features in Severe SARS-CoV-2 Infection. N. Engl. J. Med. 2020;382:2268&#x2013;2270. doi: 10.1056/NEJMc2008597.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2008597</ArticleId><ArticleId IdType="pmc">PMC7179967</ArticleId><ArticleId IdType="pubmed">32294339</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogers J.P., Chesney E., Oliver D., Pollak T.A., McGuire P., Fusar-Poli P., Zandi M.S., Lewis G., David A.S. Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: A systematic review and meta-analysis with comparison to the COVID-19 pandemic. Lancet Psychiatry. 2020;7:611&#x2013;627. doi: 10.1016/S2215-0366(20)30203-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2215-0366(20)30203-0</ArticleId><ArticleId IdType="pmc">PMC7234781</ArticleId><ArticleId IdType="pubmed">32437679</ArticleId></ArticleIdList></Reference><Reference><Citation>Soriano J.B., Murthy S., Marshall J.C., Relan P., Diaz J. V A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect. Dis. 2022;22:e102&#x2013;e107. doi: 10.1016/S1473-3099(21)00703-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00703-9</ArticleId><ArticleId IdType="pmc">PMC8691845</ArticleId><ArticleId IdType="pubmed">34951953</ArticleId></ArticleIdList></Reference><Reference><Citation>Masvekar R.R., Kosa P., Jin K., Dobbs K., Stack M.A., Castagnoli R., Quaresima V., Su H.C., Imberti L., Notarangelo L.D., et al. Prognostic value of serum/plasma neurofilament light chain for COVID-19-associated mortality. Ann. Clin. Transl. Neurol. 2022;9:622&#x2013;632. doi: 10.1002/acn3.51542.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.51542</ArticleId><ArticleId IdType="pmc">PMC9082006</ArticleId><ArticleId IdType="pubmed">35313387</ArticleId></ArticleIdList></Reference><Reference><Citation>Eng L.F. Glial fibrillary acidic protein (GFAP): The major protein of glial intermediate filaments in differentiated astrocytes. J. Neuroimmunol. 1985;8:203&#x2013;214. doi: 10.1016/S0165-5728(85)80063-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0165-5728(85)80063-1</ArticleId><ArticleId IdType="pubmed">2409105</ArticleId></ArticleIdList></Reference><Reference><Citation>Chmielewska N., Szyndler J., Makowska K., Wojtyna D., Maciejak P., P&#x142;a&#x17a;nik A. Looking for novel, brain-derived, peripheral biomarkers of neurological disorders. Neurol. Neurochir. Pol. 2018;52:318&#x2013;325. doi: 10.1016/j.pjnns.2018.02.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pjnns.2018.02.002</ArticleId><ArticleId IdType="pubmed">29478670</ArticleId></ArticleIdList></Reference><Reference><Citation>Amalia L. Glial Fibrillary Acidic Protein (GFAP): Neuroinflammation Biomarker in Acute Ischemic Stroke. J. Inflamm. Res. 2021;14:7501&#x2013;7506. doi: 10.2147/JIR.S342097.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/JIR.S342097</ArticleId><ArticleId IdType="pmc">PMC8722682</ArticleId><ArticleId IdType="pubmed">35002283</ArticleId></ArticleIdList></Reference><Reference><Citation>Khalil M., Teunissen C.E., Otto M., Piehl F., Sormani M.P., Gattringer T., Barro C., Kappos L., Comabella M., Fazekas F., et al. Neurofilaments as biomarkers in neurological disorders. Nat. Rev. Neurol. 2018;14:577&#x2013;589. doi: 10.1038/s41582-018-0058-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41582-018-0058-z</ArticleId><ArticleId IdType="pubmed">30171200</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan A., Nixon R.A. Neurofilament Proteins as Biomarkers to Monitor Neurological Diseases and the Efficacy of Therapies. Front. Neurosci. 2021;15:689938. doi: 10.3389/fnins.2021.689938.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2021.689938</ArticleId><ArticleId IdType="pmc">PMC8503617</ArticleId><ArticleId IdType="pubmed">34646114</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaetani L., Blennow K., Calabresi P., Di Filippo M., Parnetti L., Zetterberg H. Neurofilament light chain as a biomarker in neurological disorders. J. Neurol. Neurosurg. Psychiatry. 2019;90:870&#x2013;881. doi: 10.1136/jnnp-2018-320106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2018-320106</ArticleId><ArticleId IdType="pubmed">30967444</ArticleId></ArticleIdList></Reference><Reference><Citation>Frontera J.A., Boutajangout A., Masurkar A.V., Betensky R.A., Ge Y., Vedvyas A., Debure L., Moreira A., Lewis A., Huang J., et al. Comparison of serum neurodegenerative biomarkers among hospitalized COVID-19 patients versus non-COVID subjects with normal cognition, mild cognitive impairment, or Alzheimer&#x2019;s dementia. Alzheimer&#x2019;s Dement. 2022;18:899&#x2013;910. doi: 10.1002/alz.12556.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/alz.12556</ArticleId><ArticleId IdType="pmc">PMC9011610</ArticleId><ArticleId IdType="pubmed">35023610</ArticleId></ArticleIdList></Reference><Reference><Citation>Aamodt A.H., H&#xf8;gest&#xf8;l E.A., Popperud T.H., Holter J.C., Dyrhol-Riise A.M., Tonby K., Stiksrud B., Quist-Paulsen E., Berge T., Barratt-Due A., et al. Blood neurofilament light concentration at admittance: A potential prognostic marker in COVID-19. J. Neurol. 2021;268:3574&#x2013;3583. doi: 10.1007/s00415-021-10517-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-021-10517-6</ArticleId><ArticleId IdType="pmc">PMC7980743</ArticleId><ArticleId IdType="pubmed">33743046</ArticleId></ArticleIdList></Reference><Reference><Citation>Prudencio M., Erben Y., Marquez C.P., Jansen-West K.R., Franco-Mesa C., Heckman M.G., White L.J., Dunmore J.A., Cook C.N., Lilley M.T., et al. Serum neurofilament light protein correlates with unfavorable clinical outcomes in hospitalized patients with COVID-19. Sci. Transl. Med. 2021;13:eabi7643. doi: 10.1126/scitranslmed.abi7643.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abi7643</ArticleId><ArticleId IdType="pmc">PMC8432951</ArticleId><ArticleId IdType="pubmed">34131052</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper J., Stukas S., Hoiland R.L., Fergusson N.A., Thiara S., Foster D., Mitra A., Stoessl J.A., Panenka W.J., Sekhon M.S., et al. Quantification of Neurological Blood-Based Biomarkers in Critically Ill Patients With Coronavirus Disease 2019. Crit. Care Explor. 2020;2:e0238. doi: 10.1097/CCE.0000000000000238.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCE.0000000000000238</ArticleId><ArticleId IdType="pmc">PMC7535554</ArticleId><ArticleId IdType="pubmed">33063038</ArticleId></ArticleIdList></Reference><Reference><Citation>De Lorenzo R., Lor&#xe9; N.I., Finardi A., Mandelli A., Cirillo D.M., Tresoldi C., Benedetti F., Ciceri F., Rovere-Querini P., Comi G., et al. Blood neurofilament light chain and total tau levels at admission predict death in COVID-19 patients. J. Neurol. 2021;268:4436&#x2013;4442. doi: 10.1007/s00415-021-10595-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-021-10595-6</ArticleId><ArticleId IdType="pmc">PMC8108733</ArticleId><ArticleId IdType="pubmed">33973106</ArticleId></ArticleIdList></Reference><Reference><Citation>Parasher A. COVID-19: Current understanding of its Pathophysiology, Clinical presentation and Treatment. Postgrad. Med. J. 2021;97:312&#x2013;320. doi: 10.1136/postgradmedj-2020-138577.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/postgradmedj-2020-138577</ArticleId><ArticleId IdType="pmc">PMC10017004</ArticleId><ArticleId IdType="pubmed">32978337</ArticleId></ArticleIdList></Reference><Reference><Citation>Havdal L.B., Berven L.L., Selvakumar J., Stiansen-Sonerud T., Leegaard T.M., Tjade T., Zetterberg H., Blennow K., Wyller V.B.B. Neurological Involvement in COVID-19 Among Non-Hospitalized Adolescents and Young Adults. Front. Neurol. 2022;13:915712. doi: 10.3389/fneur.2022.915712.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2022.915712</ArticleId><ArticleId IdType="pmc">PMC9257204</ArticleId><ArticleId IdType="pubmed">35812102</ArticleId></ArticleIdList></Reference><Reference><Citation>Ameres M., Brandstetter S., Toncheva A.A., Kabesch M., Leppert D., Kuhle J., Wellmann S. Association of neuronal injury blood marker neurofilament light chain with mild-to-moderate COVID-19. J. Neurol. 2020;267:3476&#x2013;3478. doi: 10.1007/s00415-020-10050-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-020-10050-y</ArticleId><ArticleId IdType="pmc">PMC7345451</ArticleId><ArticleId IdType="pubmed">32647900</ArticleId></ArticleIdList></Reference><Reference><Citation>Conen D., Sch&#xf6;n T., Aeschbacher S., Par&#xe9; G., Frehner W., Risch M., Risch L. Genetic and phenotypic determinants of blood pressure and other cardiovascular risk factors (GAPP) Swiss. Med. Wkly. 2013;143:w13728. doi: 10.4414/smw.2013.13728.</Citation><ArticleIdList><ArticleId IdType="doi">10.4414/smw.2013.13728</ArticleId><ArticleId IdType="pubmed">23299990</ArticleId></ArticleIdList></Reference><Reference><Citation>Risch M., Grossmann K., Aeschbacher S., Weideli O.C., Kovac M., Pereira F., Wohlwend N., Risch C., Hillmann D., Lung T., et al. Investigation of the use of a sensor bracelet for the presymptomatic detection of changes in physiological parameters related to COVID-19: An interim analysis of a prospective cohort study (COVI-GAPP) BMJ Open. 2022;12:e058274. doi: 10.1136/bmjopen-2021-058274.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2021-058274</ArticleId><ArticleId IdType="pmc">PMC9240454</ArticleId><ArticleId IdType="pubmed">35728900</ArticleId></ArticleIdList></Reference><Reference><Citation>Khalil M., Pirpamer L., Hofer E., Voortman M.M., Barro C., Leppert D., Benkert P., Ropele S., Enzinger C., Fazekas F., et al. Serum neurofilament light levels in normal aging and their association with morphologic brain changes. Nat. Commun. 2020;11:812. doi: 10.1038/s41467-020-14612-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-14612-6</ArticleId><ArticleId IdType="pmc">PMC7010701</ArticleId><ArticleId IdType="pubmed">32041951</ArticleId></ArticleIdList></Reference><Reference><Citation>Thiel S.L., Weber M.C., Risch L., Wohlwend N., Lung T., Hillmann D., Ritzler M., Risch M., Kohler P., Vernazza P., et al. Flattening the curve in 52 days: Characterisation of the COVID-19 pandemic in the Principality of Liechtenstein&#x2014;An observational study. Swiss. Med. Wkly. 2020;150:w20361. doi: 10.4414/smw.2020.20361.</Citation><ArticleIdList><ArticleId IdType="doi">10.4414/smw.2020.20361</ArticleId><ArticleId IdType="pubmed">33105020</ArticleId></ArticleIdList></Reference><Reference><Citation>Goncalves Cabecinhas A.R., Roloff T., Stange M., Bertelli C., Huber M., Ramette A., Chen C., Nadeau S., Gerth Y., Yerly S., et al. SARS-CoV-2 N501Y Introductions and Transmissions in Switzerland from Beginning of October 2020 to February 2021&#x2014;Implementation of Swiss-Wide Diagnostic Screening and Whole Genome Sequencing. Microorganisms. 2021;9:677. doi: 10.3390/microorganisms9040677.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/microorganisms9040677</ArticleId><ArticleId IdType="pmc">PMC8064472</ArticleId><ArticleId IdType="pubmed">33806013</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen C., Nadeau S.A., Topolsky I., Manceau M., Huisman J.S., Jablonski K.P., Fuhrmann L., Dreifuss D., Jahn K., Beckmann C., et al. Quantification of the spread of SARS-CoV-2 variant B.1.1.7 in Switzerland. Epidemics. 2021;37:100480. doi: 10.1016/j.epidem.2021.100480.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.epidem.2021.100480</ArticleId><ArticleId IdType="pmc">PMC8452947</ArticleId><ArticleId IdType="pubmed">34488035</ArticleId></ArticleIdList></Reference><Reference><Citation>Newcombe V.F.J., Ashton N.J., Posti J.P., Glocker B., Manktelow A., Chatfield D.A., Winzeck S., Needham E., Correia M.M., Williams G.B., et al. Post-acute blood biomarkers and disease progression in traumatic brain injury. Brain. 2022;145:2064&#x2013;2076. doi: 10.1093/brain/awac126.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awac126</ArticleId><ArticleId IdType="pmc">PMC9326940</ArticleId><ArticleId IdType="pubmed">35377407</ArticleId></ArticleIdList></Reference><Reference><Citation>Zimmermann P., Curtis N. Why Does the Severity of COVID-19 Differ With Age? Pediatr. Infect. Dis. J. 2022;41:e36&#x2013;e45. doi: 10.1097/INF.0000000000003413.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/INF.0000000000003413</ArticleId><ArticleId IdType="pmc">PMC8740029</ArticleId><ArticleId IdType="pubmed">34966142</ArticleId></ArticleIdList></Reference><Reference><Citation>van Lierop Z.Y.G.J., Verbek I.M.W., van Uffelen K.W.J., Koel-Simmelink M.J.A., In&#x2019;t Veld L., Killestein J., Teunissen C. Pre-analytical stability of serum biomarkers for neurological disease: Neurofilament-light, glial fibrillary acidic protein and contactin-1. Clin. Chem. Lab. Med. 2022;60:842&#x2013;850. doi: 10.1515/cclm-2022-0007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/cclm-2022-0007</ArticleId><ArticleId IdType="pubmed">35333481</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>